(PSYCHIATRIC TIMES) - Mortality in elderly patients with dementia markedly and progressively increases with extended use of antipsychotics, according to the first long-term controlled study of risk in this population. Earlier evidence of this risk was from short-term trials not exceeding 14 weeks.
Clive Ballard, MD, King’s College London, and colleagues1 recently reported on the dementia antipsychotic withdrawal trial (DART-AD), a 12-month, placebo-controlled study of 165 patients with Alzheimer disease, with a follow-up of 54 months. The mean age of patients was 85 years. Participants had to have received at least 3 months of antipsychotic medication for behavioral or psychiatric symptoms. Patients were randomized to continue antipsychotic medication treatment or to switch to placebo. The antipsychotics were those most commonly prescribed for this population in the United Kingdom—thioridazine, chlorpromazine, trifluoperazine, haloperidol, and risperidone.
The cumulative probability of survival for the patients who received antipsychotic medication for 1 year was 70%, compared with 77% in patients who received placebo. After 2 years, those who continued to receive antipsychotic medication had a 46% probability of survival, compared with 71% for those not being treated with antipsychotics. Mortality after 3 years of antipsychotic treatment was about double that without medication.
“The results further highlight the need to seek less harmful alternatives for the long-term treatment of behavioral symptoms in Alzheimer’s patients,” Ballard said in a press release from the Alzheimer’s Research Trust in the United Kingdom, which funded the study.
For full article, please visit: